Management of Systolic Hypertension in Peripheral Arterial Disease

Blood Pressure Targets

The European Society of Cardiology recommends aiming for a systolic blood pressure of 120-129 mmHg in most patients with peripheral arterial disease (PAD) and hypertension, provided treatment is well tolerated 1, 2
The American College of Cardiology suggests that the traditional target of <140/90 mmHg is now considered insufficient for PAD patients 4, 2
The European Society of Cardiology advises against targeting systolic blood pressure <120 mmHg, as this may worsen limb perfusion and is associated with higher cardiovascular event rates (J-curve phenomenon) 3

The American College of Cardiology recommends that ACE inhibitors or ARBs should be the initial pharmacological choice for hypertension management in PAD patients, regardless of baseline blood pressure levels 3, 2
The European Society of Cardiology states that these agents provide cardiovascular benefits beyond blood pressure reduction, including a 25% reduction in myocardial infarction, stroke, or vascular death 3
The American College of Cardiology notes that ramipril specifically reduced cardiovascular events by 25% in PAD patients in the HOPE trial 3

The European Society of Cardiology recommends adding a dihydropyridine calcium channel blocker (CCB) or thiazide/thiazide-like diuretic to the ACE inhibitor/ARB when monotherapy is insufficient 1, 5
The European Society of Cardiology suggests preferably using fixed-dose single-pill combinations to improve adherence 1

The European Society of Cardiology recommends targeting LDL-C <55 mg/dL (<1.4 mmol/L) with ≥50% reduction from baseline in all PAD patients with hypertension 6, 2
The American College of Cardiology suggests initiating high-intensity statin therapy immediately in all PAD patients with hypertension 6, 4
The European Society of Cardiology recommends clopidogrel 75 mg daily as the preferred antiplatelet therapy over aspirin for symptomatic PAD 4, 7

The American College of Cardiology advises against aggressively lowering systolic blood pressure below 120 mmHg, as this may compromise limb perfusion and increase cardiovascular events 3
The European Society of Cardiology warns against delaying or substituting exercise therapy with medications alone, as supervised exercise is as important as pharmacotherapy 7
The European Society of Cardiology recommends against using dual RAS blockade (ACE inhibitor + ARB combination) 1

The European Society of Cardiology suggests assessing medication adherence, limb symptoms, and cardiovascular risk factors at least annually in all PAD patients with hypertension 7
The European Society of Cardiology recommends evaluating for left ventricular dysfunction, as 20-30% of PAD patients have concurrent heart failure 8
The European Society of Cardiology advises screening for atrial fibrillation (present in ~12% of PAD patients) and initiating anticoagulation if CHA₂DS₂-VASc score ≥2 8, 6